Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07058077 für Heterozygote Familiäre Hypercholesterinämie (HeFH) ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
MerckEine Studie zu Enlicitide Decanoate (MK-0616, ein oraler PCSK9-Inhibitor) bei Kindern und Jugendlichen mit heterozygoter familiärer Hypercholesterinämie (MK-0616-029) Phase 2, Phase 3 153 Jugendliche
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07058077 untersucht Behandlung im Zusammenhang mit Heterozygote Familiäre Hypercholesterinämie (HeFH). Diese interventionsstudie der Phase 2 Phase 3 hat den Status offene rekrutierung und startete am 21. August 2025. Es ist geplant, 153 Teilnehmer aufzunehmen. Durchgeführt von Merck wird der Abschluss für 23. Januar 2037 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 13. März 2026 aktualisiert.
Kurzbeschreibung
This study is designed to learn if enlicitide decanoate is safe and effective to treat children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and high amounts of low-density lipoprotein cholesterol (LDL-C) in the blood.
The goals of this study are to learn about the safety of enlicitide and if children tolerate it, what happens to enlicitide in a child's body over time, and if enlicitide wor...
Mehr anzeigenOffizieller Titel
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia
Erkrankungen
Heterozygote Familiäre Hypercholesterinämie (HeFH)Weitere Studien-IDs
- 0616-029
- U1111-1314-5796 (Registerkennung) (UTN)
- 2024-519068-42-00 (Registerkennung) (EU CT)
NCT-Nummer
Studienbeginn (tatsächlich)
2025-08-21
Zuletzt aktualisiert
2026-03-13
Studienende (vorauss.)
2037-01-23
Geplante Rekrutierung
153
Studientyp
Interventionsstudie
PHASE
Phase 2
Phase 3
Phase 3
Status
Offene Rekrutierung
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Vierfach verblindet
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellPart A: Enlicitide Decanoate Participants receive enlicitide decanoate orally once daily (QD) at a dosage determined by age for up to 2 weeks. | Enlicitide Decanoate Enlicitide decanoate taken by mouth |
ExperimentellPart B: Enlicitide Decanoate Participants receive enlicitide decanoate QD at a dosage determined by age for up to 24 weeks. | Enlicitide Decanoate Enlicitide decanoate taken by mouth |
Placebo-VergleichspräparatPart B: Placebo Participants receive placebo orally QD for up to 24 weeks. | PLACEBO Placebo tablet matched to enlicitide decanoate taken by mouth |
ExperimentellOpen-Label Extension: Enlicitide Decanoate Participants who complete either Part A or Part B may enroll in this open-label extension arm. Participants in the extension arm receive enlicitide decanoate QD at a dosage determined by age for up to 3 years. | Enlicitide Decanoate Enlicitide decanoate taken by mouth |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Part A: Maximum Plasma Concentration (Cmax) of Enlicitide | Blood samples will be collected to determine the Cmax of enlicitide. | At designated timepoints (up to 24 hours postdose on day 14) |
Part A: Area Under the Concentration-Time Curve from 0 to 24 Hours (AUC0-24) of Enlicitide | Blood samples will be collected to determine the AUC0-24 of enlicitide. | At designated timepoints (up to 24 hours postdose on day 14) |
Part B: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) | Blood samples will be collected to determine the percent change from baseline in LDL-C. | Baseline and Week 24 |
Number of Participants Who Experience an Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately 188 weeks |
Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately 180 weeks |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Part B: Percent Change from Baseline in Apolipoprotein B (ApoB) | Blood samples will be collected to determine the percent change from baseline in apolipoprotein B. | Baseline and week 24 |
Part B: Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) | Blood samples will be collected to determine the percent change from baseline in non-HDL-C. | Baseline and week 24 |
Part B: Percent Change from Baseline in Lipoprotein (a) (Lp(a)) | Blood samples will be collected to determine the percent change from baseline in Lp(a). | Baseline and week 24 |
Part B: Percentage of Participants With LDL-C <130 mg/dL at Week 24 | The percentage of participants with LDL-C \<130 mg/dL at week 24 will be reported. | Week 24 |
Part B: Percentage of Participants With ≥50% LDL-C LDL-C Reduction from Baseline at Week 24 | The percentage of participants with ≥50% LDL-C reduction from baseline at week 24 will be reported. | Baseline and week 24 |
Part B: Percentage of Participants With LDL-C <100 mg/dL at Week 24 | The percentage of participants with LDL-C \<100 mg/dL at week 24 will be reported. | Week 24 |
Change in Carotid Intima-media Thickness (cIMT) | Ultrasound measurements will be performed to determine the change from baseline in cIMT. | Baseline and week 24 |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind
Mindestalter
6 Years
Zugelassene Geschlechter
Alle
Inclusion criteria include, but are not limited to:
- Has possible or definite diagnosis of HeFH based on a locally accepted diagnostic algorithm or diagnosis by genetic testing results
- Has a fasted LDL-C value (evaluated by the central laboratory) that is ≥130 mg/dL
- Is receiving either an optimized daily dose of statin (± nonstatin LLT); or a nonstatin LLT with documented intolerance to at least 2 different statins or refusal of statin therapy by the participant or legally acceptable representative
- Is on a stable dose of all background LLTs for at least 30 days prior to screening, with no medication or dose changes planned during participation in Part A or Part B
Exclusion criteria include, but are not limited to:
- Has a history of homozygous FH based on genetic or clinical criteria, or history of known compound heterozygous FH, or double heterozygous FH
- Has a history of nephrotic syndrome
- Has any clinically significant malabsorption condition based on principal investigator assessment
- Was previously treated/is being treated with certain other cholesterol lowering medications, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout
MerckZentrale Studienkontakte
Kontakt: Toll Free Number, 1-888-577-8839, [email protected]
21 Studienstandorte in 12 Ländern
Antwerpen
UZ Antwerpen ( Site 0601), Edegem, Antwerpen, 2650, Belgium
Study Coordinator, Kontakt, +323 821 32 51
Offene Rekrutierung
Delaware
Nemours/Alfred I. duPont Hospital for Children ( Site 0001), Wilmington, Delaware, 19803, United States
Study Coordinator, Kontakt, 302-651-6600
Offene Rekrutierung
District of Columbia
Children's National Medical Center ( Site 0015), Washington D.C., District of Columbia, 20010, United States
Study Coordinator, Kontakt, 202-476-5000
Offene Rekrutierung
Florida
Excel Medical Clinical Trials ( Site 0008), Boca Raton, Florida, 33434, United States
Study Coordinator, Kontakt, 561-529-4356
Offene Rekrutierung
Georgia
Children's Healthcare of Atlanta Cardiology ( Site 0026), Atlanta, Georgia, 30329, United States
Study Coordinator, Kontakt, 404-256-2593
Offene Rekrutierung
Victoria
Monash Children s Hospital ( Site 1603), Clayton, Victoria, 3168, Australia
Study Coordinator, Kontakt, +61385723000
Offene Rekrutierung
Ceará
Universidade Federal Do Ceara ( Site 0201), Fortaleza, Ceará, 60430270, Brazil
Study Coordinator, Kontakt, +558533668590
Offene Rekrutierung
Incor - Instituto do Coracao ( Site 0200), São Paulo, 05403900, Brazil
Study Coordinator, Kontakt, +551126615450
Offene Rekrutierung
Beijing Municipality
Beijing Anzhen Hospital. Capital Medical University ( Site 1917), Beijing, Beijing Municipality, 100029, China
Study Coordinator, Kontakt, 010-64412431
Offene Rekrutierung
Zhejiang
The Children's Hospital of Zhejiang University School of Medicine ( Site 1905), Hangzhou, Zhejiang, 310057, China
Study Coordinator, Kontakt, 0571-86036545
Offene Rekrutierung
Atlántico
Clinica de la Costa S.A.S. ( Site 0400), Barranquilla, Atlántico, 080020, Colombia
Study Coordinator, Kontakt, +57 3133894240
Offene Rekrutierung
Departamento de Córdoba
Oncomédica S.A.S ( Site 0401), Montería, Departamento de Córdoba, 230002, Colombia
Study Coordinator, Kontakt, +57 3135342052
Offene Rekrutierung
Santander Department
Fundación Cardiovascular de Colombia ( Site 0402), Piedecuesta, Santander Department, 681017, Colombia
Study Coordinator, Kontakt, +573203400438
Offene Rekrutierung
Valle del Cauca Department
Fundacion Valle del Lili ( Site 0403), Cali, Valle del Cauca Department, 760032, Colombia
Study Coordinator, Kontakt, +573166237452
Offene Rekrutierung
Uusimaa
New Childrens Hospital ( Site 0800), Helsinki, Uusimaa, 00029, Finland
Study Coordinator, Kontakt, +358 9 4711
Offene Rekrutierung
North Holland
Amsterdam UMC, locatie AMC ( Site 1000), Amsterdam, North Holland, 1105 AZ, Netherlands
Study Coordinator, Kontakt, +31205666360
Offene Rekrutierung
Canterbury
New Zealand Clinical Research (Christchurch) ( Site 1700), Christchurch, Canterbury, 8011, New Zealand
Study Coordinator, Kontakt, NZCR +6433729477
Offene Rekrutierung
Central Singapore
National University Hospital-Paediatrics ( Site 1800), Singapore, Central Singapore, 117599, Singapore
Study Coordinator, Kontakt, +6567795555
Offene Rekrutierung
Asturias, Principado de
Hospital Universitario Central de Asturias ( Site 1303), Oviedo, Asturias, Principado de, 33011, Spain
Study Coordinator, Kontakt, +34985108000
Offene Rekrutierung
Navarre
COMPLEJO HOSPITALARIO DE NAVARRA ( Site 1302), Pamplona, Navarre, 31009, Spain
Study Coordinator, Kontakt, +34660021505
Offene Rekrutierung
Sheffield Childrens Hospital ( Site 1503), Sheffield, S10 2TH, United Kingdom
Study Coordinator, Kontakt, +441142717000
Offene Rekrutierung